Refine Results
- 必威体育赛事投注
- Content Type
- Analysis Platform
- Language
1 - 8 of 8 results
Applied Filters
必威体育登录手机Cellular-resolution Agilent Seahorse XF bioenergetic analyses were combined with molecular-resolution Agilent Revident Q-TOF LC/MS to investigate adaptations in cancer cells.
User Guide for SureSelect Cancer CGP Assay and SureSelect Cancer Tumor-specific Assays.
必威体育登录手机This flyer provides and overview of the family of Agilent SureSelect Community Designs designed by scientists in the Adam's Group at the Wellcome Sanger Institute.The aim of the research is to understand the genetics of cancer, using a combination...
必威体育登录手机Customize insights for tumor genomic profiling by adding new and emerging biomarkers, including TMB and MSI, with Agilent SureSelect Cancer Custom panels.必威体育登录手机Fast and easy panel design with Agilent SureDesign.
PD-L1 IHC 22C3 pharmDx (SK006) is a qualitative immunohistochemical (IHC) assay using anti-PD-L1, Clone 22C3, to detect PD-L1 in formalin-fixed, paraffin-embedded (FFPE) tumor tissues using the Autostainer Link 48.
In the present study, we present a simple metabolic preconditioning process that improves T-cell performance and bioenergetics.
This study investigates the impact of Wnt-signaling modulators on mitochondrial dysfunction.It evaluates the effects of selected drug treatments on cellular energy metabolism and cytotoxicity by comparing two distinct breast cancer cell lines: one...
This poster outlines combining the 3D tumor spheroid invasion model with the RTCA eSight's capability of live cell imaging and automatic quantification of the area of invasive protrusion can facilitate and enhance the development of new treatments...